指南与共识呼吸道感染慢阻肺

成人铜绿假单胞菌下呼吸道感染管理中国专家共识(2022)

[Chinese expert consensus on the management of lower respiratory tract infections of Pseudomonas aeruginosa in adults(2022)].
指南 / 共识 · Zhonghua Jie He He Hu Xi Za Zhi · 2022-01-01

中华医学会呼吸病学分会感染学组更新了2014版铜绿假单胞菌下呼吸道感染诊治专家共识,聚焦病原检测、诊断、抗菌治疗、综合管理与感染防控。共识指出铜绿假单胞菌是我国医院获得性肺炎第二常见革兰阴性菌(16.9%-22.0%),并明确了急慢性下呼吸道感染的诊断标准、经验性与目标性抗菌治疗原则及耐药菌治疗策略。

要点

  • 铜绿假单胞菌占我国医院获得性肺炎革兰阴性菌的16.9%-22.0%,重症社区获得性肺炎中占1.8%-8.3%。
  • 慢性下呼吸道感染诊断需满足结构性疾病基础、临床表现及1年内≥2次培养阳性(间隔≥3个月)。
  • 碳青霉烯耐药铜绿假单胞菌下呼吸道感染首选新型酶抑制剂复方制剂,头孢地尔可作为二线选择。

核心结论

  • 共识基于2014版更新,重点涵盖铜绿假单胞菌下呼吸道感染的病原检测、诊断、抗菌治疗、综合管理及感染预防与控制。

研究设计与样本

  • 中华医学会呼吸病学分会感染学组制定,以临床诊治和预防的思路与技术为重点更新专家共识。

主要发现

  • 铜绿假单胞菌是我国医院获得性肺炎第二常见革兰阴性菌,占比16.9%-22.0%。
  • 社区获得性肺炎中铜绿假单胞菌占比约1.0%,重症社区获得性肺炎中增至1.8%-8.3%。
  • 有铜绿假单胞菌感染史、支气管扩张、极重度慢阻肺或气管切开的社区获得性肺炎患者中,铜绿假单胞菌占67.0%。

关键数值与推荐

  • 慢性下呼吸道感染诊断需综合评估:基础慢性结构性肺病(如支气管扩张、囊性纤维化、慢阻肺或免疫抑制状态);下呼吸道感染临床表现;1年内≥2次(间隔至少3个月)合格下呼吸道标本检出铜绿假单胞菌。
  • 药敏试验是铜绿假单胞菌耐药检测常规方法及目标治疗依据;药敏显示可选药物活性有限时,建议联合药敏试验选择具体外相加或协同作用的药物。
  • 建议有条件时开展碳青霉烯酶表型确认等耐药机制快速检测,不推荐常规检测耐药基因指导选药。
  • 重症或具铜绿假单胞菌感染高危因素的急性下呼吸道感染患者,留取微生物标本后应经验性覆盖铜绿假单胞菌治疗。
  • 疑似铜绿假单胞菌肺炎非重症患者,经验性选用肺浓度高的单药抗铜绿假单胞菌活性药物;脓毒症或耐多药铜绿假单胞菌高危因素者,联合两种不同类别潜在敏感药物。

临床怎么用

  • 临床遇重症或有铜绿假单胞菌感染高危因素的急性下呼吸道感染患者,应在留取微生物标本后经验性覆盖铜绿假单胞菌。
  • 确诊铜绿假单胞菌下呼吸道感染后依据药敏选药,无显著基础疾病者优选肺浓度充分的单药治疗。
  • 碳青霉烯耐药或难治性耐药铜绿假单胞菌感染,优先选用体外敏感的新型酶抑制剂复方制剂,头孢地尔为二线。
  • 慢性结构性肺病患者应结合临床特征、药敏及治疗目标个体化制定抗菌方案。
  • 抗菌治疗同时落实气道廓清、氧疗、营养支持及接触隔离等综合与感染防控措施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pseudomonas aeruginosa (PA) is the second common Gram-negative bacterium for hospital acquired pneumonia (HAP) in China (16.9%-22.0%). The proportion of PA in community acquired pneumonia (CAP) was about 1.0%, while increased to 1.8%-8.3% in severe CAP. PA accounted for 67.0% of CAP in patients with a history of PA infection, bronchiectasis, very severe chronic obstructive pulmonary disease (COPD) or tracheotomy. Considering the high disease burden of lower respiratory tract infections (LRTIs) caused by PA, together with the progress in this field in recent years, the Pulmonary Infection Assembly of Chinese Thoracic Society updated the "Chinese expert consensus on the management of lower respiratory tract infections of Pseudomonas aeruginosa in adults (2014 version)", focusing on pathogen detection, diagnosis, antimicrobial therapy, comprehensive management, infection prevention and control.PA causes both acute and chronic LTRIs. Acute LRTIs mainly include pneumonia (CAP, HAP and ventilator-associated pneumonia), tracheobronchitis, lung abscess and empyema. The diagnosis of chronic LTRIs should be based on a comprehensive assessment of (1) underlying chronic structural lung diseases, such as bronchiectasis, cystic fibrosis, COPD, or immunocompromised conditions; (2) the presence of clinical manifestations of LRTIs; and (3) ≥ two times (at least 3 months apart) of PA detected from eligible lower respiratory tract specimens within 1 year. It is important to distinguish infection from colonization when PA is isolated from lower respiratory tract specimens. Drug susceptibility test is a conventional method for PA resistance detection and serves as a basis for target therapy. When drug susceptibility test shows limited activity of available agents, combined susceptibility test is suggested to select antimicrobial drugs with additive or synergistic effect in vitro for combination therapy. Rapid test of resistance mechanisms of PA isolates, such as carbapenemase phenotype confirmation tests, is recommended if available. It is recommended not to routinely detect resistance genes for choosing therapeutic agents.For patients with acute LRTIs in critical condition or with high risk factors for PA infection, empirical antimicrobial therapy covering PA should be initiated after collecting specimens for microbiological tests. In patients with suspected PA pneumonia who are not critically ill, single antimicrobial drug of anti-PA activity with high lung concentration should be selected for empirical treatment. However, for patients with a serious condition such as sepsis or with risk factors for multidrug-resistant (MDR) PA, a combination of two different classes of antimicrobial drugs that are both potentially susceptible should be used. The antimicrobial regimen should follow pharmacokinetics/pharmacodynamics principles to ensure adequate dosage and administration frequency. For confirmed PA LRTIs, antibiotics should be selected based on drug sensitivity. In patients without significant underlying diseases, single therapy of an active antimicrobial with adequate pulmonary concentration is recommended rather than combination therapy; when all the available active agents have poor intrapulmonary concentrations, combination therapy is obligatory. For LRTIs caused by carbapenem-resistant PA (CRPA) or difficult-to-treat resistance PA (DTR-PA), if an agent of new enzyme inhibitor, such as ceftolozane/tazobactam, ceftazidime/avibactam, and imipenem/cilastatin/relebactam shows in vitro sensitivity, it is recommended as the first-line choice; cefiderocol may serve as the second-line treatment. Combination therapy based on polymyxins may also be considered. Other potentially successful approaches for drug-resistant PA LRTIs include extended infusion time of β-lactams, combination therapy and inhaled antimicrobial therapy.In patients with underlying chronic structural lung diseases, the antimicrobial regimen (drug, dosage, route of administration, and duration of therapy) should be decided according to clinical features, drug sensitivity, and treatment goals (control of exacerbated symptoms, eradication of new-emerging PA, or prevention of flare-ups in patients with frequent exacerbation).Along with antimicrobial therapy, comprehensive care including airway clearance therapy (ACT), oxygen therapy, nutritional support and organ function protection should be provided. From the perspective of nosocomial infection prevention and control, isolation and prophylaxis of contact transmission are recommended to block PA transmission in addition to standard prevention measures. Targeted active screening, timely monitoring and feedback can help the prevention and control of MDR-PA. The systemic and topical use of prophylactic antimicrobials is not recommended. 铜绿假单胞菌是难治性下呼吸道感染最常见致病菌之一,由于其耐药严重和易形成生物被膜,特别是近10多年来碳青霉烯类耐药株的出现,使其治疗更为困难;同时新的治疗药物和治疗策略不断问世,有必要加以评估以指导临床合理应用。中华医学会呼吸病学分会感染学组在《铜绿假单胞菌下呼吸道感染诊治专家共识(2014年版)》的基础上进行更新,并以临床诊治和预防的思路和技术为重点,以期为临床医生规范化诊治铜绿假单胞菌下呼吸道感染提供切实可行的参考。.

来源:Zhonghua Jie He He Hu Xi Za Zhi,查看原文。版权归原作者所有。

引用

  1. [Chinese expert consensus on the management of lower respiratory tract infections of Pseudomonas aeruginosa in adults(2022)]. Zhonghua Jie He He Hu Xi Za Zhi. 2022. PMID: 35927044. doi:10.3760/cma.j.cn112147-20220407-00290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。